Psychedelic use and bipolar disorder – An investigation of recreational use and its impact on mental health

This Journal of Affective Disorders pre-print adds to several studies suggesting psilocybin can be relatively safe when treating bipolar disorders. The authors write: "Psychedelic substances such as psilocybin have recently gained attention for their potential therapeutic benefits in treating depression and other mental health problems. However, individuals with bipolar disorder (BD) have been excluded from most clinical trials due to concerns about manic switches or psychosis. This study aimed to systematically examine the effects of recreational psychedelic use in individuals with BD. Using the Time-Line Follow Back (TLFB) method, we assessed mood symptoms, substance use, and other mental health-related variables in the month before and three months following participants' most recent psychedelic experience. Results showed a significant reduction in depressive symptoms and cannabis use, an increase in the number of days without mental health symptoms, and an increase in the number of days with hallucinogen use. Importantly, no significant changes in (hypo)manic, psychotic, or anxiety symptoms were observed. These findings suggest that psychedelics may hold potential as a safe and effective treatment for BD, though further research, including randomized controlled trials, is needed."

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials

Next
Next

Randomized controlled trials of psilocybin-assisted therapy in the treatment of major depressive disorder: Systematic review and meta-analysis